Operating Lease, Right-of-Use Asset of Inhibikase Therapeutics, Inc. from 31 Dec 2021 to 30 Sep 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of lessee's right to use underlying asset under operating lease.
Summary
Inhibikase Therapeutics, Inc. quarterly Operating Lease, Right-of-Use Asset in USD history and change rate from 31 Dec 2021 to 30 Sep 2025.
  • Inhibikase Therapeutics, Inc. Operating Lease, Right-of-Use Asset for the quarter ending 30 Sep 2025 was $0, a 100% decline year-over-year.
Source SEC data
View on sec.gov
Operating Lease, Right-of-Use Asset, Quarterly (USD)
Operating Lease, Right-of-Use Asset, YoY Quarterly Change (%)

Inhibikase Therapeutics, Inc. Quarterly Operating Lease, Right-of-Use Asset (USD)

Period Value YoY Chg Change % Date Report Filed Fiscal Year Fiscal Period
Q3 2025 $0 -$133,105 -100% 30 Sep 2025 10-Q 14 Nov 2025 2025 Q3
Q2 2025 $34,918 -$128,844 -79% 30 Jun 2025 10-Q 14 Aug 2025 2025 Q2
Q1 2025 $68,719 -$124,741 -64% 31 Mar 2025 10-Q 14 May 2025 2025 Q1
Q4 2024 $101,437 -$120,790 -54% 31 Dec 2024 10-Q 14 Nov 2025 2025 Q3
Q3 2024 $133,105 -$116,985 -47% 30 Sep 2024 10-Q 14 Nov 2024 2024 Q3
Q2 2024 $163,762 -$113,330 -41% 30 Jun 2024 10-Q 14 Aug 2024 2024 Q2
Q1 2024 $193,460 -$109,803 -36% 31 Mar 2024 10-Q 15 May 2024 2024 Q1
Q4 2023 $222,227 -$106,416 -32% 31 Dec 2023 10-K 27 Mar 2025 2024 FY
Q3 2023 $250,090 -$103,160 -29% 30 Sep 2023 10-Q 14 Nov 2023 2023 Q3
Q2 2023 $277,092 30 Jun 2023 10-Q 14 Aug 2023 2023 Q2
Q1 2023 $303,263 31 Mar 2023 10-Q 15 May 2023 2023 Q1
Q4 2022 $328,643 +$328,643 31 Dec 2022 10-K 27 Mar 2024 2023 FY
Q3 2022 $353,250 30 Sep 2022 10-Q 14 Nov 2022 2022 Q3
Q4 2021 $0 31 Dec 2021 10-K 31 Mar 2023 2022 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.